When it comes to battling a rare and aggressive cancer like synovial sarcoma, the treatment options have often been limited—until now. The FDA’s recent approval of Tecelra (Amafi-Cel), the first gene therapy for adults with metastatic synovial sarcoma, not only provides new hope for patients who’ve exhausted other options but also paves the way for …
